PERSEVERE Cohort Study

Cross-source consensus on PERSEVERE Cohort Study from 1 sources and 5 claims.

1 sources · 5 claims

Where it comes from

PERSEVERE is registered on ClinicalTrials.gov as NCT07010939. — PERSEVERE: longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients – a multicentre cohort study protocol
PERSEVERE is a prospective multicentre observational cohort study of Chinese women treated for stage I-III invasive breast cancer. — PERSEVERE: longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients – a multicentre cohort study protocol
The planned study period runs from April 2025 to December 2030, with follow-up extending up to 5 years after enrolment. — PERSEVERE: longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients – a multicentre cohort study protocol
PERSEVERE aims to enrol approximately 3,000 patients to support precision, subgroup analyses, and longitudinal modelling. — PERSEVERE: longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients – a multicentre cohort study protocol
The study is coordinated by the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing with collaborating centres in multiple Chinese regions. — PERSEVERE: longitudinal assessment of quality of life and treatment toxicities in Chinese breast cancer patients – a multicentre cohort study protocol